Cardio AI Expands Portfolio with Innovative Digital Health Solutions for Cardiovascular Risk Assessment
Launch of FDA-Clearance-Track Products Includes Industry's First Women-Specific CVD Risk Platform
Cardio AI, a leader in cardiovascular artificial intelligence solutions, today announced the development of two groundbreaking additions to its product portfolio: a comprehensive suite of five digitized cardiovascular risk calculators and a pioneering women's cardiovascular health platform—the first of its kind to incorporate women-specific risk assessment capabilities.
Both products are currently undergoing the FDA clearance process, representing Cardio AI's commitment to delivering clinically validated, regulatory-compliant solutions that meet the highest standards of medical accuracy and patient safety.
Digitized CVD Risk Calculators: Precision at Your Fingertips
The new digital risk calculator platform provides healthcare providers and patients with immediate access to five evidence-based cardiovascular risk assessment tools. These digitized calculators streamline the clinical workflow while maintaining the rigor and reliability that clinicians require for informed decision-making.
Access the CVD Risk Calculators Platform:
https://cardioai-cvd-risk-calculators.vercel.app/Women's Cardiovascular Health Platform: Addressing a Critical Gap
Cardio AI's Women's Health platform addresses a long-standing gap in cardiovascular care by incorporating risk factors unique to women's health. Cardiovascular disease remains the leading cause of death among women, yet traditional risk assessment tools have historically been developed primarily using male-dominated study populations.
Industry-First Women-Specific Risk Assessment
The Women's Cardiovascular Health Platform is the only solution of its kind to incorporate pregnancy-related complications, hormonal factors, and other sex-specific variables that significantly impact a woman's cardiovascular risk profile.
Access the Women's CVD Health Platform:
https://cardio-ai-womens-cvd-health.vercel.app/Commitment to Regulatory Excellence
Both products are being developed in accordance with FDA requirements for medical device software, underscoring Cardio AI's dedication to clinical validation and patient safety. The pursuit of FDA clearance demonstrates the company's commitment to meeting rigorous regulatory standards and providing healthcare providers with tools they can trust.
These innovative platforms represent a significant advancement in cardiovascular risk assessment technology, combining clinical expertise with cutting-edge digital solutions to improve patient outcomes and streamline healthcare delivery.
About Cardio AI
Cardio AI develops innovative artificial intelligence solutions for cardiovascular disease prevention, diagnosis, and management. By combining cutting-edge technology with clinical expertise, Cardio AI is transforming how healthcare providers assess and manage cardiovascular risk.
For more information about Cardio AI's expanding product portfolio, please visit www.cardioailive.com or contact [email protected].